RxDoctor Payments Data

Gregory Hanson, MD

Urology · Fridley, MNNPI 1699881748

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Procept Biorobotics Corporation at 47.9% of the total.

$6,539in general payments, 2019–2025

Across 87 payments — averaging $75.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$3K
  • Gyrus ACMI, Inc.$1K
  • Medivators Inc.$500
  • Astellas Pharma US Inc$239
  • Angiodynamics, Inc.$174
  • Intuitive Surgical$144
  • plus $1K from 24 others

What the payments were for

  • Consulting fees$1,10017%
  • Speaking & faculty fees$5008%
  • Travel & lodging$2,45037%
  • Food & beverage$2,47338%
  • Gifts$170%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,539 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$189,323
Medicare patients
499
Services billed
2,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide82$1,061,447
OrgovyxRelugolix134$333,402
ErleadaApalutamide16$211,021
MyrbetriqMirabegron129$124,004
Abiraterone Acetate60$53,590
GemtesaVibegron29$24,481
Tamsulosin Hcl708$11,412
Dutasteride144$4,822
Finasteride173$3,213
Trospium Chloride ErTrospium Chloride11$2,333
Solifenacin Succinate50$2,225
Alfuzosin Hcl ErAlfuzosin Hcl86$2,158
Tolterodine Tartrate ErTolterodine Tartrate18$1,735
Oxybutynin Chloride ErOxybutynin Chloride92$1,721
Potassium Citrate ErPotassium Citrate29$1,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$239$1,185,451211 claims
Johnson & JohnsonErleada$99$211,02116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.

Other urology in Fridley

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →